Opaleye Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,220
Closed -$1.2M 51
2021
Q3
$1.2M Sell
1,220
-958
-44% -$1.2M 0.22% 44
2021
Q2
$3.25M Buy
2,178
+241
+12% +$525K 0.54% 40
2021
Q1
$5.21M Buy
1,937
+159
+9% +$315K 0.77% 40
2020
Q4
$3.5M Sell
1,778
-2,220
-56% -$5.22M 0.46% 43
2020
Q3
$10.8M Sell
3,998
-2,958
-43% -$7.38M 2.11% 16
2020
Q2
$19.8M Sell
6,956
-1,982
-22% -$6.39M 3.99% 6
2020
Q1
$23.9M Sell
8,938
-140
-2% -$418K 6.33% 4
2019
Q4
$23.2M Buy
9,078
+7,478
+467% +$9.74M 4.54% 2
2019
Q3
$1.5M Buy
+1,600
New +$1.82M 0.54% 39

Other funds holding APTO

Opaleye Management's APTO Position: Q4 2021 in Review

Opaleye Management sold out of Aptose Biosciences, Inc. (APTO) in Q4 2021, closing a stake of 1,220 shares — an estimated $1.2M sold.

Opaleye Management first reported a position in APTO in Q3 2019 and held it in 9 quarters. The position peaked at $23.9M in Q1 2020. 58 funds tracked by Wall St. Rank hold APTO as of Q4 2021.

  • Opaleye Management reported no remaining Aptose Biosciences, Inc. position as of Q4 2021 after selling out during the quarter.
  • Opaleye Management sold 1,220 Aptose Biosciences, Inc. shares in Q4 2021, an estimated $1.2M.
  • Opaleye Management first reported a position in Aptose Biosciences, Inc. in Q3 2019 and held it in 9 quarters.
  • Opaleye Management's Aptose Biosciences, Inc. position peaked at $23.9M in Q1 2020.
  • 58 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2021.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.